Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Ana Luiza Mylla Boso, Erica Gasperi, Leticia Fernandes, Vital Paulino Costa, Monica Alves Department of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, BrazilCorrespondence: Ana Luiza Mylla BosoDepartment of Ophthalmology and Otorhinola...
Guardado en:
Autores principales: | Mylla Boso AL, Gasperi E, Fernandes L, Costa VP, Alves M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/552c9dcb71f4444bbb29957e38784b07 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
por: Stalmans I, et al.
Publicado: (2020) -
Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016) -
Glaucoma therapy: preservative-free for all?
por: Thygesen J
Publicado: (2018) -
Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease
por: Nasser L, et al.
Publicado: (2018) -
Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate N, et al.
Publicado: (2020)